Annual report pursuant to Section 13 and 15(d)

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
Dec. 31, 2015
Equity [Abstract]
Convertible Preferred Stock	7. Convertible Preferred Stock *Series A Convertible Preferred Stock* As of January 1, 2014, Cocrystal Discovery, Inc. had outstanding shares of its Series A Preferred Stock (Cocrystal Discovery Series A). The holders of Cocrystal Discovery Series A preferred stock were entitled to receive cumulative dividends at a rate of $0.1153 per share per annum. The preferred stock dividends were payable when and if declared by the Companys Board of Directors. No dividends were ever declared on the Cocrystal Discovery Series A. In connection with the merger with Biozone in January 2014, the Company exchanged the above Cocrystal Discovery Series A for a new Series B Convertible Preferred Stock. See below for more information. The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. In connection with the merger with RFS Pharma in November 2014, the Company created a new series of Series A Preferred Stock (Series A). The Series A shares automatically converted into 340,760,802 shares of the Companys common stock on March 3, 2015 as a result of the Companys shareholders approving an increase in the number of the Companys authorized common shares to 800,000,000. The Series A shares were classified as mezzanine equity in the Companys consolidated balance sheet as of December 31, 2014, because at that date such shares could potentially have been redeemed by its holders for events that were outside the Companys control. No accretion to redemption value was required, as redemption was not probable. *Series B Convertible Preferred Stock* In connection with the merger with Biozone, the Company issued to Cocrystal Discoverys Series A and Common security holders 1,000,000 shares of the Companys Series B Convertible Preferred Stock (Series B). The Series B shares automatically converted into 205,083,086 shares of the Companys common stock on March 3, 2015 as a result of the Companys shareholders approving an increase in the number of the Companys authorized common shares to 800,000,000.

Convertible Preferred Stock

12 Months Ended

Dec. 31, 2015

7. Convertible Preferred Stock

Series A Convertible Preferred Stock

As of January 1, 2014, Cocrystal Discovery, Inc. had outstanding shares of its Series A Preferred Stock (Cocrystal Discovery Series A). The holders of Cocrystal Discovery Series A preferred stock were entitled to receive cumulative dividends at a rate of $0.1153 per share per annum. The preferred stock dividends were payable when and if declared by the Companys Board of Directors. No dividends were ever declared on the Cocrystal Discovery Series A.

In connection with the merger with Biozone in January 2014, the Company exchanged the above Cocrystal Discovery Series A for a new Series B Convertible Preferred Stock. See below for more information.

The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. In connection with the merger with RFS Pharma in November 2014, the Company created a new series of Series A Preferred Stock (Series A). The Series A shares automatically converted into 340,760,802 shares of the Companys common stock on March 3, 2015 as a result of the Companys shareholders approving an increase in the number of the Companys authorized common shares to 800,000,000. The Series A shares were classified as mezzanine equity in the Companys consolidated balance sheet as of December 31, 2014, because at that date such shares could potentially have been redeemed by its holders for events that were outside the Companys control. No accretion to redemption value was required, as redemption was not probable.

Series B Convertible Preferred Stock

In connection with the merger with Biozone, the Company issued to Cocrystal Discoverys Series A and Common security holders 1,000,000 shares of the Companys Series B Convertible Preferred Stock (Series B). The Series B shares automatically converted into 205,083,086 shares of the Companys common stock on March 3, 2015 as a result of the Companys shareholders approving an increase in the number of the Companys authorized common shares to 800,000,000.